Clinical Values of Automated Electronic Alert for Acute Kidney Injury
NCT ID: NCT02793167
Last Updated: 2023-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2000 participants
INTERVENTIONAL
2016-03-31
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Automated Electronic Alert for Acute Kidney Injury on the Outcomes of Hospitalized Patients
NCT03736304
Electronic Warning Systems in Diagnosis and Treatment of AKI
NCT03119480
Optimizing Electronic Alerts for Acute Kidney Injury
NCT02753751
Electronic Alert for Acute Kidney Injury in Geriatric Wards
NCT04464031
AKI Management Using Electronic Alerts
NCT03538769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators randomly divided the patients into two groups:
1. Usual care : patients will receive standard clinical care by the primary physicians
2. AKI alert : an AKI alert will be sent to the the doctor in charge. Our team of kidney experts would give a suggestion if the the doctor in charge issue consultation applications.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Usual care
patients will receive standard clinical care by the doctor in charge.
No interventions assigned to this group
AKI alert
an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
AKI alert
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AKI alert
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients with End stage renal disease
* patients \<18 years of age
* patients dissenting from participation according to the Ethics application
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XinLing Liang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
XinLing Liang
Director of Blood Purification Center of Guangdong General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nephrology Dept,Guangdong General Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GGH2016-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.